AdScientiam x Merck Healthcare: innovating for gMG

AdScientiam and Merck KGaA announce a new collaboration aimed at improving the management of people living with generalized myasthenia gravis (gMG).

This collaboration will lead to a prospective, multicenter pilot study, planned to start in 2026 across several European countries.

The goal is to evaluate an investigational software medical device combining a mobile application, a wearable, and ePROS to collect digital measures in real-life conditions, without supervision.

This solution is designed to support patients and healthcare professionals in monitoring symptoms, and assessing disease impact.

Check out our Press releases for all the details.

Share